Benralizumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Benralizumab and local guidelines before prescribing.

Anti-IL-5R monoclonal antibody

Mechanism

Anti-IL-5 receptor alpha monoclonal antibody.

Uses

Severe eosinophilic asthma, EGPA.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Headache, pharyngitis, hypersensitivity.

Interactions

Few.

Contraindications and cautions

Active parasitic infection

Monitoring

Asthma control

Pregnancy and breastfeeding

Limited data

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Depletes eosinophils; treat helminth infection first.

More from the textbook: uses, cautions and other points
Where it is discussed in the book